New Insights into the SAR and Binding Modes of Bis(hydroxyphenyl)thiophenes and -benzenes: Influence of Additional Substituents on 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1) Inhibitory Activity and Selectivity

被引:72
|
作者
Bey, Emmanuel [1 ]
Marchais-Oberwinkler, Sandrine [1 ]
Negri, Matthias [1 ]
Kruchten, Patricia [1 ]
Oster, Alexander [1 ]
Klein, Tobias [1 ]
Spadaro, Alessandro [1 ]
Werth, Ruth [1 ]
Frotscher, Martin [1 ]
Birk, Barbara [1 ]
Hartmann, Rolf W. [1 ]
机构
[1] Univ Saarland, D-66041 Saarbrucken, Germany
关键词
BREAST-CANCER; NONSTEROIDAL INHIBITORS; BIOLOGICAL EVALUATION; GENETIC ALGORITHM; DESIGN; DEHYDROGENASE; ESTRADIOL; POTENT; EXPRESSION; FLUORINE;
D O I
10.1021/jm901195w
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
17 beta-Hydroxystcroid dehydrogenase type 1 (17 beta-HSD1) is responsible for the catalytic reduction of weakly active E1 to highly potent E2. E2 stimulates the proliferation of hormone-dependent diseases via activation of the estrogen receptor alpha (ER alpha). Because of the overexpression of 17 beta-HSD1 in mammary tumors, this enzyme should be an attractive target for the treatment of estrogen-dependent pathologies. Recently, we have reported on a series of potent 17 beta-HSD1 inhibitors: bis(hydroxyphenyl) azoles, thiophenes, and benzenes. In this paper, different substituents are introduced into the core structure and the biological properties of the corresponding inhibitors are evaluated. Computational methods and analysis of different X-rays of 17 beta-HSD1 lead to identification of two different binding modes for these inhibitors. The fluorine compound 23 exhibits an IC50 of 8 nM and is the most potent nonsteroidal inhibitor described so far. It also shows a high selectivity (17 beta-HSD2, ER alpha) and excellent pharmacokinetic properties after peroral application to rats.
引用
收藏
页码:6724 / 6743
页数:20
相关论文
共 25 条
  • [1] Design, Synthesis, Biological Evaluation and Pharmacokinetics of Bis(hydroxyphenyl) substituted Azoles, Thiophenes, Benzenes, and Aza-Benzenes as Potent and Selective Nonsteroidal Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1)
    Bey, Emmanuel
    Marchais-Oberwinkler, Sandrine
    Werth, Ruth
    Al-Soud, Yaseen A.
    Kruchten, Patricia
    Oster, Alexander
    Frotscher, Martin
    Birk, Barbara
    Hartmann, Rolf W.
    JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (21) : 6725 - 6739
  • [2] Hydroxybenzothiazoles as New Nonsteroidal Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1)
    Spadaro, Alessandro
    Negri, Matthias
    Marchais-Oberwinkler, Sandrine
    Bey, Emmanuel
    Frotscher, Martin
    PLOS ONE, 2012, 7 (01):
  • [3] The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17β-Hydroxysteroid Dehydrogenase (17β-HSD) type 1 and type 2
    Al-Soud, Yaseen A.
    Bey, Emmanuel
    Oster, Alexander
    Marchais-Oberwinkler, Sandrine
    Werth, Ruth
    Kruchten, Patricia
    Frotscher, Martin
    Hartmann, Rolf W.
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2009, 301 (1-2) : 212 - 215
  • [4] 17β-Hydroxysteroid Dehydrogenase 3 (17β-HSD3), a Regulator of 11β-Hydroxysteroid Dehydrogenase 1 (11β-HSD1) Activity in Rat Leydig Cell.
    Latif, S. A.
    Ge, R.
    Sottas, C. M.
    Shen, M.
    Morris, D. J.
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [5] Bicyclic Substituted Hydroxyphenylmethanone Type Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1): The Role of the Bicyclic Moiety
    Oster, Alexander
    Klein, Tobias
    Henn, Claudia
    Werth, Ruth
    Marchais-Oberwinkler, Sandrine
    Frotscher, Martin
    Hartmann, Rolf W.
    CHEMMEDCHEM, 2011, 6 (03) : 476 - 487
  • [6] Structure-activity study in the class of 6-(3′-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitors
    Marchais-Oberwinkler, Sandrine
    Frotscher, Martin
    Ziegler, Erika
    Werth, Ruth
    Kruchten, Patricia
    Messinger, Josef
    Thole, Hubert
    Hartmann, Rolf W.
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2009, 301 (1-2) : 205 - 211
  • [7] Structural Basis for Species Specific Inhibition of 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1): Computational Study and Biological Validation
    Klein, Tobias
    Henn, Claudia
    Negri, Matthias
    Frotscher, Martin
    PLOS ONE, 2011, 6 (08):
  • [8] Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases
    Bey, Emmanuel
    Marchais-Oberwinkler, Sandrine
    Kruchten, Patricia
    Frotscher, Martin
    Werth, Ruth
    Oster, Alexander
    Alguel, Oztekin
    Neugebauer, Alexander
    Hartmann, Rolf W.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (12) : 6423 - 6435
  • [9] Bicyclic Substituted Hydroxyphenylmethanones as Novel Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1) for the Treatment of Estrogen-Dependent Diseases
    Oster, Alexander
    Hinsberger, Stefan
    Werth, Ruth
    Marchais-Oberwinkler, Sandrine
    Frotscher, Martin
    Hartmann, Rolf W.
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (22) : 8176 - 8186
  • [10] Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives:: Potent and selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases
    Frotscher, Mar-Tin
    Ziegler, Erika
    Marchais-Oberwinkler, Sandrine
    Kruchten, Patricia
    Neugebauer, Alexander
    Fetzer, Ludivine
    Scherer, Christiane
    Mueller-Vieira, Ursula
    Messinger, Josef
    Thole, Hubert
    Hartmann, Rolf W.
    JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (07) : 2158 - 2169